Sonida Senior Living stock
SNDANYSESonida Senior Living, Inc., HealthcareISIN US1404752032
32Score 32 out of 100, Weak
Price and trend
49 / 100
Price history
+3.5% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 9.2% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 23% below its 52-week high. Largest decline in 20 years: 98% (April 2015 to May 2023).
Chart figures for advanced users
- SMA 50$36.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$36.53
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$30.30
- The lowest closing price of the last twelve months.
- Resistance$43.07
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sonida Senior Living, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.63B, is number 34 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $381.14M (up 25.2% year on year) and a loss of $70.78M.
- For fiscal 2026, analysts expect on average revenue of $729.73M (up 91.5%) and adjusted earnings per share of −$3.59.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 677 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 726% since 2020.Capital allocation 25
- Loss-makingLoss of $129.77M over the last 12 months.Fundamentals 17
- High debtDebt 1.87 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 41
The score is held back by profitability and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 70% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −8%, operating −15%, net −19%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Mar 2027in 118 days
- Last reported
- 5 Nov 2026EPS reported −$0.72 (expected −$0.54)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.590.0%
- Revenue
- $729.73M0.0%
- Earnings per share
- −$1.590.0%
- Revenue
- $860.25M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $10.99M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Simanovsky MichaelSale
1 Sept 2026, Board
- Shares
- 97,581
- Price
- $38.42
- Value
- $3.75M
- Simanovsky MichaelSale
28 Aug 2026, Board
- Shares
- 26,407
- Price
- $38.35
- Value
- $1.01M
- Simanovsky MichaelSale
27 Aug 2026, Board
- Shares
- 15,000
- Price
- $39.00
- Value
- $585,000
Show 4 more
- Simanovsky MichaelSale
26 Aug 2026, Board
- Shares
- 15,086
- Price
- $40.94
- Value
- $617,580
- Simanovsky MichaelSale
25 Aug 2026, Board
- Shares
- 115,000
- Price
- $40.71
- Value
- $4.68M
- Harris Benjamin PSale
14 Aug 2026, Board
- Shares
- 6,269
- Price
- $39.79
- Value
- $249,441
- Harris Benjamin PSale
13 May 2026, Board
- Shares
- 2,500
- Price
- $37.46
- Value
- $93,654
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Sonida Senior Living
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Agilon HealthAGL $1.93B48
- EmeisEMEIS.PA $1.92B41
- AttendoATT.ST $1.87B65
- Healthcare Services GroupHCSG $1.7B70
- AmbeaAMBEA.ST $1.64B70
- Astrana HealthASTH $1.63B54
- U.S. Physical TherapyUSPH $1.49B55
- AMN Healthcare ServicesAMN $1.47B65
ETFs that hold Sonida Senior Living
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Show 3 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2013)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.